MedTrace Logo

Matching Patients With Hematologic Malignancy to Adequate Clinical Trials

NCT02758080 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2017-10-26

No results posted yet for this study

Summary

A molecular profile of a patient with hematologic malignancy, for whom standard-of-care had failed, is identified using next generation sequencing. Patients are assigned to early clinical trials of targeted agent based on the molecular profiling or physician's choice. The improvement of outcomes in the intention-to-treat population is investigated.

Conditions

Interventions

OTHER

Matching on the basis of molecular analysis

OTHER

Matching on the basis of physician's choice

Sponsors & Collaborators

  • The Korea Health Technology R&D Project through the Korea Health Industry Development Institute

    collaborator UNKNOWN

  • Ministry of Health, Republic of Korea

    collaborator OTHER_GOV

  • Seoul National University Hospital

    lead OTHER

Principal Investigators

  • Youngil Koh, MD · Seoul National University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-01-31
Primary Completion
2019-06-30
Completion
2019-06-30

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02758080 on ClinicalTrials.gov